Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

EU delivers enough doses to vaccinate 70% of adults, von der Leyen says

Published 10/07/2021, 10:07
Updated 10/07/2021, 11:25
© Reuters. European Commission President Ursula von der Leyen attends a plenary session at the European Parliament in Strasbourg, France July 7, 2021. Patrick Hertzog/Pool via REUTERS

BRUSSELS (Reuters) - The European Union has delivered enough coronavirus vaccine doses to member states to reach a target to fully vaccinate at least 70% of adults in the bloc, European Commission chief Ursula von der Leyen said in a statement on Saturday.

Von der Leyen, who had tweeted on May 9 that the EU was on track to meet its goal of inoculating 70% of adults by summer, urged EU countries to increase vaccinations and said about 500 million doses would be distributed across the union by Sunday.

"The European Union has kept its word. This weekend we have delivered enough vaccines to member states to be in a position to vaccinate fully at least 70% of the EU adults this month," von der Leyen said in a video statement.

"But COVID-19 is not yet defeated. We are prepared to deliver more vaccines, including against new variants," said von der Leyen, who faced sharp criticism at the start of 2021 for failing to ensure companies delivered contracted vaccines.

The EU has a longer-term goal of having enough vaccines to immunise its entire eligible population by the end of September, and said in May it was confident of having enough vaccines to reach that target.

Von der Leyen added in her latest statement that the EU was prepared to deliver more doses, including vaccines which act against new variants.

The EU, which is coordinating vaccine purchasing for its member states, has been largely relying on the jab developed by BioNTech and Pfizer (NYSE:PFE), but is also purchasing a number of other vaccines.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The Commission said last week EU countries had ordered nearly 40 million additional doses of the vaccine produced by Johnson & Johnson (NYSE:JNJ).

The Commission previously warned that it expected the highly contagious Delta variant of the coronavirus to become dominant in Europe this summer, citing estimates from the EU disease prevention agency.

Recent studies have shown that the Delta variant reduces the effectiveness of vaccines against symptomatic infection, but two doses of COVID-19 vaccines are highly effective in preventing serious illness and deaths.

Latest comments

murderers ! u gonna see in a year or two what u done
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.